Study Maps Brain Genetics Across 231 Human Donors
A preprint integrating sequencing and profiling of prefrontal cortex tissue identifies a SOX5 enhancer as a therapeutic candidate.
Updated on Nov. 17, 2026 in Alzheimer’s

Researchers posted a preprint on bioRxiv on November 17, 2026, integrating whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors. The work identified a SOX5 enhancer as a therapeutic candidate for haploinsufficient neurodevelopmental disorders.
Why it matters
The study links genetic risk for neurodevelopmental and psychiatric traits to neuronal profiles, and neurodegenerative risk to microglia, offering a map of where disease-linked genetic variation acts in the brain. Identifying regulatory elements that can be modulated gives researchers a potential route toward treatments for conditions driven by reduced gene dosage.
The evidence is a multi-omic profiling study drawn from 231 human prefrontal cortex donors spanning ages from six postconceptional weeks to 92 years, compared against 24 brain-related genetic traits. The preprint does not yet report whether its therapeutic candidate, the SOX5 enhancer, produces effects in living systems.
The players
bioRxiv
A preprint server operated by Cold Spring Harbor Laboratory that hosts early versions of research manuscripts before formal peer review.
The details
Researchers combined whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling to identify thousands of expression, chromatin accessibility, and splicing quantitative trait loci. Colocalization analyses linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia, and CRISPR activation of the SOX5 enhancer increased transcript and protein abundance.
Timeline
November 15, 2026: Preprint manuscript DOI dated.
November 17, 2026: Preprint published on bioRxiv.
Big Picture
The work extends efforts such as the NIH BRAIN Initiative Cell Atlas Network, which catalogs brain cell types, by connecting those cell-type profiles to specific genetic risk and to a candidate regulatory element for intervention.
For now, the findings are preclinical and do not change any treatment options for patients. Readers with neurodevelopmental or psychiatric conditions should continue to rely on their clinicians, as the candidate regulatory element has not yet been tested for safety or effectiveness in people.
The takeaway
Genetic risk for brain disorders appears concentrated in specific cell types, which can guide where future therapies are targeted. Watching for the peer-reviewed version will show whether the SOX5 enhancer result holds up.
Further reading
Explore more on Alzheimer’s research and brain health coverage.
Source note: This article includes information reported by Biorxiv.



